Oral Nutritional Supplement in Adults With or at Risk of Malnutrition

NCT07426406 | Completed

• 1 other identifier: BM05
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 3

Brief Summary

This is a multi-center, prospective, non-randomized, non-blinded, single-arm, single treatment study.

Conditions

Gastrointestinal Tolerance

Outcome Measures

Primary Outcomes (1)

• Gastrointestinal Tolerance

  Bristol Stool Form Scale; Stool is classified into 7 groups (Types 1-7) with Type 3-4 as ideal stools

  Study Day 1 - Study Day 7

Secondary Outcomes (2)

• Nutritional Supplement Palatability

  Study Day 1 - Study Day 7

• Nutritional Supplement Compliance

  Study Day 1 - Study Day 7

Other Outcomes (2)

• Adverse Events

  Baseline - Study Day 8

• Anthropometric

  Baseline and Study Day 8

Study Arms (1)

Experimental Nutrition Product

EXPERIMENTAL

2 servings per day

Other: Experimental Nutrition Product

Interventions

Experimental Nutrition Product OTHER

High energy, high protein oral nutritional supplement

Experimental Nutrition Product

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant has voluntarily signed and dated an ICF approved by an EC and provided applicable privacy authorization prior to any participation in the study.
• Participant (male or female) is ≥ 18 years of age.
• Participant is considered by a dietitian or clinician as malnourished or at risk for malnutrition based on current use of ONS, recently identified as malnourished or at risk of malnutrition based on a validated malnutrition screening tool, or has had weight loss within the last two months as a result of a hospitalization or a chronic illness.
• Participant currently has normal GI function.
• Participant requires ONS as assessed by a dietitian or clinician and is willing to comply with the study protocol for at least 7 days.
• Non-pregnant, non-lactating female, at least 6 weeks postpartum prior to the screening visit. A urine pregnancy test is required for all female participants unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to the screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
• If participant is of childbearing potential, the participant must agree to use effective forms of birth control methods for the duration of the study.

You may not qualify if:

• Participant has severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder affecting abilities to answer questions, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.
• Participant has a history of uncontrolled diabetes as evidenced by HbA1c of \> 9% within the last six months.
• Participant is currently taking or has taken antibiotics within 1 week prior to the feeding period (SDay 1 may be delayed until such time that the participant has completed a one-week washout period).
• Participant has undergone major GI surgery less than 3 months prior to enrollment in the study.
• Participant has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment.
• Participant has an allergy or intolerance to any ingredient in the study nutritional product.
• Participant has an aversion to all of the flavours of product being assessed.
• Participant has an obstruction of the GI tract precluding ingestion or absorption of the study product, inflammatory bowel disease, gastric esophageal reflux disease, short bowel syndrome, or other major gastrointestinal disease-causing symptoms including (but not limited to) uncontrollable severe diarrhea, nausea, or vomiting. Exceptions include well-controlled reflux symptoms defined as no change in medication in the last 3 months.
• Participant is currently taking medications/dietary supplements/substances that could profoundly modulate metabolism or affect gastrointestinal motility. Exceptions include multivitamins/mineral supplements, optical steroids, and inhaled steroids for asthma.
• Participation in another study that has not been approved as a concomitant study by Abbott.
• Participant has a clinical condition that is contraindicated with this product as determined by the clinician in accordance with standard of care.

Sponsors & Collaborators

• Abbott Nutrition: lead

Study Sites (3)

North Coast Medical

Newquay, Cornwall, TR7 1RU, United Kingdom

Location

Atlantic Medical Group

Penzance, Cornwall, TR18 3DX, United Kingdom

Location

Hull University Teaching Hospital

Anlaby, Hull, HU3 2PA, United Kingdom

Location

Study Officials

• Maria Camprubi, PhD

  Abbott

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 17, 2026
• First Posted: February 23, 2026
• Study Start: March 22, 2026
• Primary Completion: June 30, 2026
• Study Completion: June 30, 2026
• Last Updated: July 1, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

GB (3)